Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus

2005 ◽  
Vol 30 (2) ◽  
pp. 201-204 ◽  
Author(s):  
K. A. Finucane ◽  
C. B. Archer
2007 ◽  
Vol 67 (4) ◽  
pp. 542-546 ◽  
Author(s):  
B Vander Cruyssen ◽  
L Nogueira ◽  
J Van Praet ◽  
D Deforce ◽  
D Elewaut ◽  
...  

Background:Different methods exist to demonstrate anti-citrullinated protein/peptide antibodies (ACPA).Aims:To evaluate discrepancy between four ACPA tests.Patients and methods:Population 1 consisted of patients with a new diagnostic problem, including 86 patients with rheumatoid arthritis (RA) and 450 patients without RA. Population 2 consisted of 155 patients with RA who had long-standing disease. Population 3 consisted of 188 patients with psoriatic arthritis and in population 4 there were 192 patients with systemic lupus erythematosus. Populations 1 and 2 were tested with the anti-human fibrinogen antibody (AhfibA) test, anti-CCP2 from Eurodiagnostica (CCP2-euro), anti-CCP2 from Pharmacia (CCP2-phar) and anti-CCP3 test by Inova (CCP3). Samples were annotated as discrepant if positive in one and negative in at least one other test. Each discrepant sample was re-analysed in a different run. Populations 3 and 4 were analysed in the CCP2-euro and AhFibA test.Results:In population 1, ACPA positivity was found in 17 of 450 (3.8%) patients without RA; 14 (82%) of these 17 samples were discrepant. In contrast, 61 of 86 (70.9%) patients with RA were ACPA positive of whom 18 of 61 (29.5%) were discrepant (70.9% vs. 29.5%, p<0.001). The discrepancies between tests could be partly attributed to borderline results, inter-assay discrepancy and inter-test variability. They were more prevalent in patients with systemic lupus erythematosus who were ACPA positive than in those with psoriatic arthritis who were ACPA positive.Conclusions:Discrepancy between different ACPA tests was observed attributable to the occurrence of borderline results, inter-assay variability and mainly to inter-test variability. The lowest inter-test discrepancy is observed between tests that use the same substrate.


2020 ◽  
pp. 263-306
Author(s):  
Charlotte Frise ◽  
Sally Collins

This chapter covers rheumatic diseases in the pregnant patient. It gives background, clinical features, and management in the pregnant patient for rheumatoid arthritis, Sjögren’s syndrome, psoriatic arthritis, systemic lupus erythematosus, antiphospholipid syndrome, and ankylosing spondylitis among others. It also covers systemic sclerosis, osteoporosis, and other musculoskeletal problems. Medications and the use of biologics in pregnancy are also discussed, with reference to breastfeeding.


Author(s):  
Tanya M. Monaghan ◽  
James D. Thomas

This chapter concerns locomotive medicine, and covers rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, Paget’s disease, tophaceous gout, Marfan’s syndrome, systemic sclerosis, vasculitis, systemic lupus erythematosus, rickets, Dupuytren’s contracture, trigger finger, and Charcot’s joint.


2021 ◽  
pp. 209-239
Author(s):  
Altaf Abdulkhaliq

AbstractBone is a target tissue in many inflammatory diseases including rheumatic diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and psoriatic arthritis.


Sign in / Sign up

Export Citation Format

Share Document